Janet Wittes

27.5k total citations · 9 hit papers
161 papers, 15.1k citations indexed

About

Janet Wittes is a scholar working on Statistics and Probability, Cardiology and Cardiovascular Medicine and Statistics, Probability and Uncertainty. According to data from OpenAlex, Janet Wittes has authored 161 papers receiving a total of 15.1k indexed citations (citations by other indexed papers that have themselves been cited), including 70 papers in Statistics and Probability, 34 papers in Cardiology and Cardiovascular Medicine and 30 papers in Statistics, Probability and Uncertainty. Recurrent topics in Janet Wittes's work include Statistical Methods in Clinical Trials (62 papers), Meta-analysis and systematic reviews (28 papers) and Health Systems, Economic Evaluations, Quality of Life (19 papers). Janet Wittes is often cited by papers focused on Statistical Methods in Clinical Trials (62 papers), Meta-analysis and systematic reviews (28 papers) and Health Systems, Economic Evaluations, Quality of Life (19 papers). Janet Wittes collaborates with scholars based in United States, United Kingdom and Canada. Janet Wittes's co-authors include Bertram Pitt, Faı̈ez Zannad, A Castaigne, A.J. Pérez Pérez, Robert Cody, Willem J. Remme, John J.V. McMurray, Scott D. Solomon, Erica Brittain and Ann G. Zauber and has published in prestigious journals such as New England Journal of Medicine, JAMA and Circulation.

In The Last Decade

Janet Wittes

156 papers receiving 14.5k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure

2000 2.4k citations Bertram Pitt, Faı̈ez Zannad et al. profile →
Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention

2005 1.6k citations Scott D. Solomon, John J.V. McMurray et al. New England Journal of Medicine profile →
Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease

2013 784 citations Heidi Christ‐Schmidt, John J.V. McMurray et al. New England Journal of Medicine profile →
Celecoxib for the Prevention of Colorectal Adenomatous Polyps

2006 751 citations Janet Wittes, Scott D. Solomon et al. New England Journal of Medicine profile →
Relation of Gemfibrozil Treatment and Lipid Levels With Major Coronary Events

2001 716 citations Sander J. Robins, Janet Wittes et al. profile →
Bardoxolone Methyl and Kidney Function in CKD with Type 2 Diabetes

2011 707 citations Heidi Christ‐Schmidt, Janet Wittes et al. New England Journal of Medicine profile →
Replacement Therapy for Alpha₁-Antitrypsin Deficiency Associated with Emphysema

1987 485 citations Janet Wittes, Ronald G. Crystal et al. New England Journal of Medicine profile →
Patiromer in Patients with Kidney Disease and Hyperkalemia Receiving RAAS Inhibitors

2014 453 citations Janet Wittes, Heidi Christ‐Schmidt et al. New England Journal of Medicine profile →
Efficacy, Safety, and Durability of Voretigene Neparvovec-rzyl in RPE65 Mutation–Associated Inherited Retinal Dystrophy

2019 276 citations Zi‐Fan Yu, Janet Wittes et al. profile →

Peers

Countries citing papers authored by Janet Wittes

Since Specialization

Citations

This map shows the geographic impact of Janet Wittes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Janet Wittes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Janet Wittes more than expected).

Fields of papers citing papers by Janet Wittes

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Janet Wittes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Janet Wittes. The network helps show where Janet Wittes may publish in the future.

Co-authorship network of co-authors of Janet Wittes

This figure shows the co-authorship network connecting the top 25 collaborators of Janet Wittes. A scholar is included among the top collaborators of Janet Wittes based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Janet Wittes. Janet Wittes is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Aspirin in primary prevention: Undue reliance on an uninformative trial led to misinformed clinical guidelines 2025 ·Clinical Trials ·Janet Wittes, David L. DeMets, KyungMann Kim, Dennis G. Maki, Marc A. Pfeffer, J. Michael Gaziano, Panagiota Kitsantas, Charles H. Hennekens, Sarah Wood	1
2	Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension 2025 ·New England Journal of Medicine ·John M. Flack, Michel Azizi, Jenifer M. Brown, Jamie P. Dwyer, Jakub Fronczek, Erika Jones, Daniel S Olsson, Shira Perl, Hirotaka Shibata, (unknown), Ulrica Wilderäng, Janet Wittes, Bryan Williams	11
3	Baxdrostat for uncontrolled and resistant hypertension: rationale and design of the Phase 3 clinical trials BaxHTN, BaxAsia, and Bax24 2025 ·Hypertension Research ·John M. Flack, Michel Azizi, Jenifer M. Brown, Jamie P. Dwyer, Erika Jones, Aina S. Lihn, (unknown), Daniel S Olsson, Shira Perl, Hirotaka Shibata, Ji-Guang Wang, Ulrica Wilderäng, Janet Wittes, Bryan Williams	3
4	The Data Monitoring Committee: A Collective or a Collection? 2023 ·Therapeutic Innovation & Regulatory Science ·Janet Wittes, Thomas Fleming, David L. DeMets, Susan S. Ellenberg, Hertzel C. Gerstein, Marc A. Pfeffer, Frank W. Rockhold, Salim Yusuf, Charles H. Hennekens	1
5	Analysis of on-treatment cancer safety events with daprodustat versus conventional erythropoiesis-stimulating agents—post hoc analyses of the ASCEND-ND and ASCEND-D trials 2022 ·Nephrology Dialysis Transplantation ·Ajay Singh, Finnian R. Mc Causland, Brian Claggett, Christoph Wanner, Andrzej Więcek, Michael B. Atkins, Kevin Carroll, Vlado Perkovic, John J.V. McMurray, Janet Wittes, Steven Snapinn, (unknown), Amy M. Meadowcroft, (unknown), Tara DiMino, Stephen Mallett, Alexander R. Cobitz, Scott D. Solomon	8
6	Data monitoring committee interim reports: We must get there soon! 2021 ·Clinical Trials ·David L. DeMets, Janet Wittes	8
7	Treatment of HF in an Era of Multiple Therapies 2020 ·JACC Heart Failure ·Ankeet S. Bhatt, William T. Abraham, JoAnn Lindenfeld, Michael Bristow, Peter E. Carson, G. Michael Felker, Gregg C. Fonarow, Stephen J. Greene, Mitchell A. Psotka, Scott D. Solomon, Norman Stockbridge, John R. Teerlink, Muthiah Vaduganathan, Janet Wittes, Mona Fiuzat, Christopher M. O’Connor, Javed Butler	18
8	The Modern Randomized Clinical Trial: Is it Time to Sharpen a Blunt Instrument? 2019 ·Janet Wittes	1
9	Reports to Independent Data Monitoring Committees: An Appeal for Clarity, Completeness, and Comprehensibility 2017 ·Therapeutic Innovation & Regulatory Science ·Kevin A. Buhr, Matthew Downs, (unknown), Robin Bechhofer, Janet Wittes	12
10	First-line treatment of metastatic renal cell carcinoma after COMPARZ and PISCES 2015 ·Current Opinion in Urology ·Manuela Schmidinger, Janet Wittes	6
11	The Impact of Kidney Function on Outcomes Following High Risk Myocardial Infarction: Findings from 27 610 Patients 2013 ·European Journal of Heart Failure ·George V. Moukarbel, Zi‐Fan Yu, Kenneth Dickstein, (unknown), Janet Wittes, John J.V. McMurray, Bertram Pitt, Faı̈ez Zannad, Marc A. Pfeffer, Scott D. Solomon	16
12	Some practical problems in implementing randomization 2010 ·Clinical Trials ·(unknown), Kathryn Tucker, Heidi Christ‐Schmidt, Janet Wittes	18
13	Reply to DS Kalman, MF Mc Carty, and V Juturu and JR Komorowski 2003 ·American Journal of Clinical Nutrition ·Michelle D. Althuis, Janet Wittes	11
14	Glucose and insulin responses to dietary chromium supplements: a meta-analysis,, 2002 ·American Journal of Clinical Nutrition ·Michelle D. Althuis, (unknown), Elizabeth Ludington, Janet Wittes	177
15	Approaches to monitoring the results of long-term disease prevention trials: Examples from the Women's Health Initiative 1996 ·Controlled Clinical Trials ·Laurence S. Freedman, Garnet L. Anderson, Victor Kipnis, Ross L. Prentice, (unknown), Jacques E. Rossouw, Janet Wittes, David L. DeMets	52
16	Rationale and design of the Department of Veterans Affairs high-density lipoprotein cholesterol Intervention Trial (HIT) for secondary prevention of coronary artery disease in men with low high-density lipoprotein cholesterol and desirable low-density lipoprotein cholesterol 1993 ·The American Journal of Cardiology ·Hanna E. Bloomfield, Sander J. Robins, Marika K. Iwane, William E. Boden, Marshall B. Elam, Carol L. Fye, David J. Gordon, Ernst J. Schaefer, Gordon Schectman, Janet Wittes	81
17	Behind closed doors: The data monitoring board in randomized clinical trials 1993 ·Statistics in Medicine ·Janet Wittes	32
18	Use of a Highly Purified α1-Antitrypsin Standard to Establish Ranges for the Common Normal and Deficient α1-Antitrypsin Phenotypes 1991 ·CHEST Journal ·Mark Brantly, Janet Wittes, Claus Vogelmeier, (unknown), G A Fells, Ronald G. Crystal	143
19	Surrogate endpoints in clinical trials: Cardiovascular diseases 1989 ·Statistics in Medicine ·Janet Wittes, Edward Lakatos, Jeffrey L. Probstfield	165
20	Febrile seizures: long-term management of children with fever-associated seizures. Summary of an NIH consensus statement. 1980 ·BMJ ·Edwin L. Kendig, Paul Dyken, (unknown), (unknown), (unknown), (unknown), B. J. Wilder, Janet Wittes	28

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact